Back to 
JPMorgan Chase & Co.
JPMorgan Chase & Co.
INKT
6 quarters
Position history for JPMorgan Chase & Co.'s holdings in MiNK Therapeutics, Inc.
Yes. JPMorgan Chase holds 9 shares of INKT (MiNK Therapeutics), worth $107, as of its Q2 2026 13F filing. The share count is unchanged from Q1 2026. JPMorgan Chase has held INKT since Q1 2025, across 6 quarterly 13F filings.
Current Value
$107
Current Shares
9
Total Value Change
-$152
Total Shares Change
-21
Quarter-by-Quarter History
Other major holders of INKT: Vanguard Capital Management LLC, Vanguard Group Inc., DnB Asset Management AS